A multicenter clinical trial reveals that inflammatory pathways contribute to asthma flare-ups in children with eosinophilic asthma, even with targeted T2 therapies. Eosinophilic asthma is characterized by excess eosinophils that cause chronic inflammation in the lungs. Despite using mepolizumab, which reduces T2 inflammation, some children still face exacerbations, indicating other inflammatory mechanisms at play. The study analyzed data from a clinical trial involving eosinophilic asthma patients in low-income urban settings. Researchers aim to understand the complex interactions between various inflammatory types and asthma exacerbation triggers, including viral factors.
Eosinophilic asthma is characterized by high levels of eosinophils, a type of white blood cell involved in the body's immune response. While eosinophils typically help fight infections, in eosinophilic asthma, they accumulate in the lungs and airways, causing chronic inflammation, swelling and damage to the respiratory system.
Even with targeted therapies against T2 inflammation, some children still experience asthma attacks. This suggests that other inflammatory pathways also play a role in exacerbations.
Collection
[
|
...
]